Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND)

June 9, 2026 6:51 AM

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $262.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst commented: "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found